A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT03254485

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03254485
Other papers using this trial's data
  • Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial JAMA, 2020-10-20 DOI, PubMed 33079154, PMC7576408 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03254485. Randomized; quadruple masking; primary purpose treatment. Start 2017-11-07 (actual); primary completion 2019-08-19 (actual). Results posted on 2022-09-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Acronym
CAPACITY-HFpEF
Intervention (Drug)
IW-1973
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Akebia Therapeutics (class: industry)
Collaborator
Cyclerion Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03254485
Content hash
e6aede9199708fac85b20d1f7f526e9022d93905c1431e599af5aea609b87cc1